These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 16538553

  • 1. Determinants of adherence to osteoporosis treatment in clinical practice.
    Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group.
    Osteoporos Int; 2006; 17(6):914-21. PubMed ID: 16538553
    [Abstract] [Full Text] [Related]

  • 2. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [Abstract] [Full Text] [Related]

  • 3. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J, Vanuga P, Payer J, Svobodník A.
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [Abstract] [Full Text] [Related]

  • 4. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
    Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group.
    J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811
    [Abstract] [Full Text] [Related]

  • 5. Adherence to anti-osteoporotic therapies: role and determinants of "spot therapy".
    Tafaro L, Nati G, Leoni E, Baldini R, Cattaruzza MS, Mei M, Falaschi P.
    Osteoporos Int; 2013 Aug; 24(8):2319-23. PubMed ID: 23404614
    [Abstract] [Full Text] [Related]

  • 6. Self-reported compliance with osteoporosis medication-qualitative aspects and correlates.
    Vytrisalova M, Blazkova S, Palicka V, Vlcek J, Cejkova M, Hala T, Pavelka K, Koblihova H.
    Maturitas; 2008 Aug; 60(3-4):223-9. PubMed ID: 18774663
    [Abstract] [Full Text] [Related]

  • 7. [Alendronate and vitamin D (Fosavance): persistence, adherence and importance of vitamin D].
    Grazio S, Morović-Vergles J.
    Reumatizam; 2007 Aug; 54(2):89-92. PubMed ID: 18351154
    [Abstract] [Full Text] [Related]

  • 8. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effect of menopause, hormone replacement therapy (HRT), alendronate (ALN), and calcium supplements on saliva.
    Yalçin F, Gurgan S, Gurgan T.
    J Contemp Dent Pract; 2005 May 15; 6(2):10-7. PubMed ID: 15915200
    [Abstract] [Full Text] [Related]

  • 11. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
    Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L, Stock JL.
    Bone; 2007 Apr 15; 40(4):843-51. PubMed ID: 17182297
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alendronate 70 therapy in elderly women with post-menopausal osteoporosis: the problem of compliance.
    Sewerynek E, Małkowski B, Karzewnik E, Stepien-Klos W, Tabaszewska M, Lasota M, Krupińska G, Glądalska A, Horst-Sikorska W, Stuss M.
    Endokrynol Pol; 2011 Apr 15; 62(1):24-9. PubMed ID: 21365575
    [Abstract] [Full Text] [Related]

  • 17. Compliance of osteoporotic patients with different treatment regimens.
    Segal E, Tamir A, Ish-Shalom S.
    Isr Med Assoc J; 2003 Dec 15; 5(12):859-62. PubMed ID: 14689753
    [Abstract] [Full Text] [Related]

  • 18. Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
    Vinicola V, Giampà E, Di Bonito M, Ferretti V, Nuvoli G, Paoletti F, Piazzini M, Ranieri M, Tuveri MA.
    Minerva Endocrinol; 2015 Sep 15; 40(3):187-93. PubMed ID: 26205647
    [Abstract] [Full Text] [Related]

  • 19. Incidence and causes for failure of treatment of women with proven osteoporosis.
    Zafran N, Liss Z, Peled R, Sherf M, Reuveni H.
    Osteoporos Int; 2005 Nov 15; 16(11):1375-83. PubMed ID: 15806322
    [Abstract] [Full Text] [Related]

  • 20. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
    Palomba S, Orio F, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F.
    Osteoporos Int; 2005 Aug 15; 16(8):943-52. PubMed ID: 15739035
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.